IS8374A - Bóluefnissamsetningar sem samanstanda af hvítfrumuboða 18 og sapónín ónæmisglæðakerfi - Google Patents

Bóluefnissamsetningar sem samanstanda af hvítfrumuboða 18 og sapónín ónæmisglæðakerfi

Info

Publication number
IS8374A
IS8374A IS8374A IS8374A IS8374A IS 8374 A IS8374 A IS 8374A IS 8374 A IS8374 A IS 8374A IS 8374 A IS8374 A IS 8374A IS 8374 A IS8374 A IS 8374A
Authority
IS
Iceland
Prior art keywords
leukocyte
vaccine compositions
compositions consisting
adjuvant system
saponin adjuvant
Prior art date
Application number
IS8374A
Other languages
English (en)
Icelandic (is)
Inventor
Elvire Marie Bruck Claudine
Marie Ghislaine Gerard Catherine
Ludmila Jonak Zdenka
Original Assignee
Glaxosmithkline Biologicals S.A.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Smithkline Beecham Corporation filed Critical Glaxosmithkline Biologicals S.A.
Publication of IS8374A publication Critical patent/IS8374A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS8374A 2003-10-13 2006-03-27 Bóluefnissamsetningar sem samanstanda af hvítfrumuboða 18 og sapónín ónæmisglæðakerfi IS8374A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0323965.4A GB0323965D0 (en) 2003-10-13 2003-10-13 Immunogenic compositions
PCT/EP2004/011620 WO2005039634A1 (en) 2003-10-13 2004-10-11 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system

Publications (1)

Publication Number Publication Date
IS8374A true IS8374A (is) 2006-03-27

Family

ID=29559205

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8374A IS8374A (is) 2003-10-13 2006-03-27 Bóluefnissamsetningar sem samanstanda af hvítfrumuboða 18 og sapónín ónæmisglæðakerfi

Country Status (17)

Country Link
US (1) US20070212329A1 (enExample)
EP (1) EP1687025A1 (enExample)
JP (1) JP2007508272A (enExample)
KR (1) KR20070054136A (enExample)
CN (1) CN1889977A (enExample)
AU (1) AU2004283457A1 (enExample)
BR (1) BRPI0415304A (enExample)
CA (1) CA2541695A1 (enExample)
CO (1) CO5700790A2 (enExample)
GB (1) GB0323965D0 (enExample)
IL (1) IL174544A0 (enExample)
IS (1) IS8374A (enExample)
MA (1) MA28149A1 (enExample)
NO (1) NO20061912L (enExample)
RU (1) RU2006111847A (enExample)
WO (1) WO2005039634A1 (enExample)
ZA (1) ZA200602950B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120011898A (ko) * 2000-02-10 2012-02-08 아보트 러보러터리즈 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법
US7524824B2 (en) * 2003-09-04 2009-04-28 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7727561B2 (en) 2001-08-31 2010-06-01 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
AU2003259827B2 (en) * 2002-08-12 2008-09-04 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US8614197B2 (en) * 2003-10-09 2013-12-24 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US7514412B2 (en) * 2003-10-09 2009-04-07 Pacific Arrow Limited Anticancer biangeloyl saponins
US7488753B2 (en) * 2003-10-09 2009-02-10 Pacific Arrow Limited Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof
EP1670491B1 (en) * 2003-10-09 2015-07-29 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
DE102004022200B4 (de) 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
US9382285B2 (en) 2004-09-07 2016-07-05 Pacific Arrow Limited Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells
US8735558B2 (en) * 2005-02-14 2014-05-27 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
US8586719B2 (en) * 2005-04-27 2013-11-19 Pacific Arrow Limited Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
DE102006008023B4 (de) 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
ES2504522T3 (es) 2006-09-08 2014-10-08 Actinium Pharmaceuticals Inc. Método para la purificación de radio a partir de diferentes fuentes
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN106310293A (zh) * 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2818178A1 (en) 2008-01-11 2014-12-31 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
NZ727616A (en) * 2008-06-27 2018-06-29 Zoetis Services Llc Novel adjuvant compositions
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
US20120277308A1 (en) 2010-07-16 2012-11-01 Pacific Arrow Limited compounds for treating cancer and other diseases
US9434677B2 (en) 2009-07-16 2016-09-06 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
US9499577B2 (en) 2009-07-16 2016-11-22 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
AU2011209399B2 (en) * 2010-01-27 2014-04-10 Glaxo Group Limited Modified tuberculosis antigens
CN103025351B (zh) * 2010-05-28 2016-08-24 佐蒂斯比利时股份有限公司 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
RU2482866C2 (ru) * 2010-10-07 2013-05-27 Общество с ограниченной ответственностью "Аллоферон" Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18
CN103998058B (zh) 2011-10-06 2021-11-05 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
GB201205361D0 (en) * 2012-03-27 2012-05-09 Univ Nottingham Trent Breast cancer assay
AU2014203977B2 (en) * 2013-01-04 2016-11-17 Obi Pharma, Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
US10166288B2 (en) 2014-10-01 2019-01-01 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
GB201522329D0 (en) * 2015-12-17 2016-02-03 Glaxosmithkline Biolog S A And Inst Nat De La Sante Et De La Rech Medicale Inserm And Université Pie Use of adjuvants for the prevention and/or treatment of autoimmune diseases
AU2017351900B2 (en) * 2016-10-31 2020-11-26 Eyegene Inc. Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
TR201907085A2 (tr) 2019-05-10 2020-11-23 Univ Yeditepe Parazi̇tleri̇n ve parazi̇tlerden elde edi̇len ekstraselüler vezi̇külleri̇n kanser tedavi̇si̇nde kullanimi
BR112022004228A2 (pt) * 2019-09-09 2022-05-31 Glaxosmithkline Biologicals Sa Composições imunoterapêuticas
WO2021115410A1 (zh) * 2019-12-13 2021-06-17 南京远大赛威信生物医药有限公司 免疫刺激组合物及其用途
WO2022034555A1 (en) * 2020-08-13 2022-02-17 Janssen Biopharma, Inc. Polynucleotide constructs and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA40597C2 (uk) * 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6355256B1 (en) * 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
WO1999056775A1 (en) * 1998-05-07 1999-11-11 Akzo Nobel N.V. Use of interleukin-18 as vaccine adjuvant
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
EP1187629B1 (en) * 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6843987B2 (en) * 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
KR20120011898A (ko) * 2000-02-10 2012-02-08 아보트 러보러터리즈 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법

Also Published As

Publication number Publication date
KR20070054136A (ko) 2007-05-28
JP2007508272A (ja) 2007-04-05
CA2541695A1 (en) 2005-05-06
IL174544A0 (en) 2006-08-01
EP1687025A1 (en) 2006-08-09
US20070212329A1 (en) 2007-09-13
WO2005039634A1 (en) 2005-05-06
RU2006111847A (ru) 2007-11-20
NO20061912L (no) 2006-06-02
MA28149A1 (fr) 2006-09-01
GB0323965D0 (en) 2003-11-19
CO5700790A2 (es) 2006-11-30
CN1889977A (zh) 2007-01-03
AU2004283457A1 (en) 2005-05-06
BRPI0415304A (pt) 2006-12-05
ZA200602950B (en) 2007-09-26

Similar Documents

Publication Publication Date Title
IS8374A (is) Bóluefnissamsetningar sem samanstanda af hvítfrumuboða 18 og sapónín ónæmisglæðakerfi
NO20055347D0 (no) Blandinger og framgangsmate for WT1-spesifikk immunterapi
EP1438074A4 (en) ADJUVANT COMPOSITIONS
EP1549135A4 (en) VACCINE COMPOSITIONS AND AUXILIARY
DK1390066T3 (da) Vaccinesammensætning
NO20050132D0 (no) Vaksinesammensetning
DK1524993T3 (da) Neisseria-vaccinesammensætning omfattende en kombination af antigener
PL2218342T3 (pl) Nowe kompozycje nutraceutyczne i ich zastosowanie
TWI369981B (en) Hmb compositions and uses thereof
NO20016173D0 (no) Gipssammensetninger og fremgangsmåter ved fremstilling derav
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1824566T3 (da) Orale sammensætninger indeholdende ekstrakter af rosmaring og beslægtede metoder
DK2322603T3 (da) Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons
AU2003259735A8 (en) Small-mer compositions and methods of use
IS6788A (is) Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation)
NO20021786D0 (no) Skumdempningsfremgangsmåter og sammensetninger
DK1523329T3 (da) Viruspartikeladjuvant
EP1450752A4 (en) MULTIVALENT VACCINE COMPOSITIONS CONTAINING STREPTOCOCCUS AND METHODS OF USE
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
EP1692279A4 (en) VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
EP1976485A4 (en) LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF
DK1337228T3 (da) Sammensætninger til fjernelse af human cerumen
DK1370141T3 (da) Fungicide sammensætninger på basis af derivat af pyridylmethylbenzamid og propamocarb
EP1583557A4 (en) VACCINE COMPOSITIONS AND METHODS
DK1484056T3 (da) Sammensætninger med langsom frigivelse og fremgangsmåde til fremstilling af disse